GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SAB Biotherapeutics Inc (NAS:SABS) » Definitions » Asset Turnover

SAB Biotherapeutics (SAB Biotherapeutics) Asset Turnover : 0.00 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is SAB Biotherapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. SAB Biotherapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. SAB Biotherapeutics's Total Assets for the quarter that ended in Mar. 2024 was $77.66 Mil. Therefore, SAB Biotherapeutics's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. SAB Biotherapeutics's annualized ROE % for the quarter that ended in Mar. 2024 was -36.51%. It is also linked to ROA % through Du Pont Formula. SAB Biotherapeutics's annualized ROA % for the quarter that ended in Mar. 2024 was -25.89%.


SAB Biotherapeutics Asset Turnover Historical Data

The historical data trend for SAB Biotherapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SAB Biotherapeutics Asset Turnover Chart

SAB Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
0.19 - - - -

SAB Biotherapeutics Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SAB Biotherapeutics's Asset Turnover

For the Biotechnology subindustry, SAB Biotherapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SAB Biotherapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SAB Biotherapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where SAB Biotherapeutics's Asset Turnover falls into.



SAB Biotherapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

SAB Biotherapeutics's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (50.905+83.941)/ 2 )
=0/67.423
=0.00

SAB Biotherapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (83.941+71.371)/ 2 )
=0/77.656
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


SAB Biotherapeutics  (NAS:SABS) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

SAB Biotherapeutics's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-20.104/55.0605
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-20.104 / 0)*(0 / 77.656)*(77.656/ 55.0605)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.4104
=ROA %*Equity Multiplier
=-25.89 %*1.4104
=-36.51 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

SAB Biotherapeutics's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-20.104/77.656
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-20.104 / 0)*(0 / 77.656)
=Net Margin %*Asset Turnover
= %*0
=-25.89 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


SAB Biotherapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of SAB Biotherapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


SAB Biotherapeutics (SAB Biotherapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2100 East 54th Street North, Sioux Falls, SD, USA, 57104
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Executives
Eddie Joe Sullivan director, 10 percent owner, officer: Chief Executive Officer 2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Michael King officer: CHIEF FINANCIAL OFFICER 2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Samuel J Reich director, officer: Executive Chairman ACUITY PHARMACEUTICALS INC, 3701 MARKET STREET, PHILADELPHIA PA 19104
Sessa Capital Im, L.p. director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Andrew Moin director 2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Sessa Capital (master), L.p. director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Im Gp, Llc director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
John Petry director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Gp, Llc director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Erick Lucera director 138 THISTLE ROAD, NORTH ANDOVER MA 08145
David Charles Link director 2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Christine E Hamilton director, 10 percent owner 225 S MAIN AVE, P O BOX 5000, SIOUX FALLS SD 57117
Scott Giberson director 2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Alexandra Kropotova officer: Chief Medical Officer RIVER OAKS TOWER, 8800 HSC PARKWAY, BYRAN TX 77807
Jeffrey G Spragens director 4400 BISCAYNE BOULEVARD, SUITE 1500, MIAMI FL 33137

SAB Biotherapeutics (SAB Biotherapeutics) Headlines

From GuruFocus